Market closed

Puma Biotechnology/$PBYI

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Ticker

$PBYI
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Los Angeles, United States

Employees

185
Website
www.pumabiotechnology.com

PBYI Metrics

BasicAdvanced
$151M
6.62
$0.47
1.08
-

$151M

1.08

$7.73

$2.23

664K

1.42

1.371

50.211

121.497

2.50%

9.73%

42.32%

6.616

0.61

2.13

8.63

4.415

6.30%

492.79%

-0.91%

-27.04%

What the Analysts think about PBYI

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Puma Biotechnology stock.

PBYI Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PBYI Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

PBYI News

AllArticlesVideos
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 weeks ago
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Business Wire·3 weeks ago
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PBYI

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Puma Biotechnology stock?

Puma Biotechnology (PBYI) has a market cap of $151M as of January 15, 2025.

What is the P/E ratio for Puma Biotechnology stock?

The price to earnings (P/E) ratio for Puma Biotechnology (PBYI) stock is 6.62 as of January 15, 2025.

Does Puma Biotechnology stock pay dividends?

No, Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Puma Biotechnology dividend payment date?

Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders.

What is the beta indicator for Puma Biotechnology?

Puma Biotechnology (PBYI) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.